OraSure Technologies (OSUR) to Release Earnings on Tuesday

Key Points

• OraSure Technologies (OSUR) is set to release its Q2 2025 earnings after the market closes on August 5th, with analysts estimating a loss of ($0.15) per share and revenue of $30.52 million.
• The stock opened at $3.35, with a one-year range between $2.36 and $4.92, reflecting a market capitalization of $250.58 million.
• Institutional investors hold approximately 93.50% of OraSure's stock, indicating strong interest from large investors, including significant increases in stakes by firms like AQR Capital Management.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $30.52 million for the quarter.

OraSure Technologies Stock Performance

Shares of NASDAQ:OSUR traded down $0.17 during trading on Friday, reaching $3.01. 928,277 shares of the stock were exchanged, compared to its average volume of 703,580. OraSure Technologies has a 12-month low of $2.36 and a 12-month high of $4.92. The firm has a market cap of $225.15 million, a price-to-earnings ratio of -7.17 and a beta of 0.27. The firm's 50-day moving average price is $3.03 and its 200 day moving average price is $3.23.

Wall Street Analyst Weigh In

OSUR has been the subject of a number of research reports. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. Evercore ISI restated an "in-line" rating and issued a $3.00 price target on shares of OraSure Technologies in a report on Monday, May 19th.

Hedge Funds Weigh In On OraSure Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of OSUR. AQR Capital Management LLC boosted its holdings in OraSure Technologies by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier's stock worth $3,511,000 after acquiring an additional 339,493 shares during the period. NewEdge Advisors LLC boosted its stake in shares of OraSure Technologies by 32,595.9% during the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier's stock valued at $161,000 after buying an additional 47,590 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of OraSure Technologies by 7.2% during the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier's stock valued at $1,366,000 after buying an additional 27,310 shares during the last quarter. Amundi purchased a new position in shares of OraSure Technologies during the 1st quarter valued at approximately $47,000. Finally, Envestnet Asset Management Inc. boosted its stake in shares of OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 8,133 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company's stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.